奥尼妥单抗-话题@MedSci

#奥尼妥单抗#

1篇内容 | 396人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2251484, encodeId=1b0f2251484b3, content=<a href='/topic/show?id=e58d60299c' target=_blank style='color:#2F92EE;'>#DLBCL#</a> <a href='/topic/show?id=edba4069ec' target=_blank style='color:#2F92EE;'>#CAR-T治疗#</a> <a href='/topic/show?id=585b1180938d' target=_blank style='color:#2F92EE;'>#奥尼妥单抗#</a>, objectTitle=Blood | CAR-T治疗后DLBCL治疗新突破：奥尼妥单抗单药疗效显著, objectType=article, longId=862754, objectId=0ab2862e5447, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240725/1721876888294_92910.jpg, objectUrl=/article/show_article.do?id=0ab2862e5447, replyNumber=0, likeNumber=21, createdTime=2025-02-11, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=0ab2862e5447, moduleTitle=Blood | CAR-T治疗后DLBCL治疗新突破：奥尼妥单抗单药疗效显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0ab2862e5447)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2251535, encodeId=5a9b225153558, content=<a href='/topic/show?id=585b1180938d' target=_blank style='color:#2F92EE;'>#奥尼妥单抗#</a>弥漫性大B细胞淋巴瘤（DLBCL）是一种侵袭性淋巴瘤，约占所有非霍奇金淋巴瘤（NHL）的30-40%, objectTitle=Blood | CAR-T治疗后DLBCL治疗新突破：奥尼妥单抗单药疗效显著, objectType=article, longId=862754, objectId=0ab2862e5447, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240725/1721876888294_92910.jpg, objectUrl=/article/show_article.do?id=0ab2862e5447, replyNumber=0, likeNumber=14, createdTime=2025-02-11, rootId=0, userName=ms4000001513304915, userId=a1646442901, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=广东省, moduleDTOList=[ModuleDTO(moduleId=0ab2862e5447, moduleTitle=Blood | CAR-T治疗后DLBCL治疗新突破：奥尼妥单抗单药疗效显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0ab2862e5447)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2221279, encodeId=8b5f22212e9be, content=<a href='/topic/show?id=f60f118092e1' target=_blank style='color:#2F92EE;'>#复发性或难治性滤泡性淋巴瘤#</a> <a href='/topic/show?id=75771122236f' target=_blank style='color:#2F92EE;'>#2期研究#</a> <a href='/topic/show?id=585b1180938d' target=_blank style='color:#2F92EE;'>#奥尼妥单抗#</a>, objectTitle=Ann. Oncol | 2期研究：奥尼妥单抗在治疗复发或难治性滤泡性淋巴瘤患者中表现出显著疗效和安全性, objectType=article, longId=839537, objectId=5a1b83953efa, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240818/1723987197001_6145188.png, objectUrl=/article/show_article.do?id=5a1b83953efa, replyNumber=0, likeNumber=51, createdTime=2024-08-19, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=5a1b83953efa, moduleTitle=Ann. Oncol | 2期研究：奥尼妥单抗在治疗复发或难治性滤泡性淋巴瘤患者中表现出显著疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5a1b83953efa)], followStatus=false, userIsMember=false, type=null, lengthMark=0)] 梅斯管理员

复发性或难治性滤泡性淋巴瘤 2期研究奥尼妥单抗

2024-08-19发表于上海

梅斯管理员

#DLBCL# #CAR-T治疗# #奥尼妥单抗#

Blood | CAR-T治疗后DLBCL治疗新突破：奥尼妥单抗单药疗效显著

2025-02-11发表于陕西省

ms4000001513304915

#奥尼妥单抗#弥漫性大B细胞淋巴瘤（DLBCL）是一种侵袭性淋巴瘤，约占所有非霍奇金淋巴瘤（NHL）的30-40%

Blood | CAR-T治疗后DLBCL治疗新突破：奥尼妥单抗单药疗效显著

2025-02-11发表于广东省

梅斯管理员

#复发性或难治性滤泡性淋巴瘤# #2期研究# #奥尼妥单抗#

Ann. Oncol | 2期研究：奥尼妥单抗在治疗复发或难治性滤泡性淋巴瘤患者中表现出显著疗效和安全性

2024-08-19发表于上海